Alemtuzumab
View article: Case Reports of Teprotumumab as Treatment for Monoclonal Antibody-Induced Thyroid Orbitopathy
Case Reports of Teprotumumab as Treatment for Monoclonal Antibody-Induced Thyroid Orbitopathy Open
Background and Clinical Significance: Targeted biologic therapies, especially monoclonal antibodies (mAbs) such as nivolumab and alemtuzumab, have revolutionized treatment for malignancies and autoimmune conditions but can cause rare immun…
View article: Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies
Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies Open
Infections remain a leading cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), reflecting both intrinsic immune dysfunction and therapy‐related immunosuppression. The pathogenesis of immunodeficiency in C…
View article: Novel Therapeutic Approaches in Pediatric Acute Lymphoblastic Leukemia
Novel Therapeutic Approaches in Pediatric Acute Lymphoblastic Leukemia Open
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, characterized by the clonal proliferation of immature lymphoid precursors. The distinction between B-cell ALL (B-ALL) and T-cell ALL (T-ALL) is fundamental, as eac…
View article: Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR)
Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR) Open
Background In the therapeutic landscape of multiple sclerosis (MS), more than a dozen disease-modifying therapies (DMT) are currently available. In Austria, only certified MS centers are authorized to prescribe DMT and are obliged to enter…
View article: Molecular Pathogenesis and Targeted Therapies in Eosinophilic Granulomatosis with Polyangiitis: An Updated Review
Molecular Pathogenesis and Targeted Therapies in Eosinophilic Granulomatosis with Polyangiitis: An Updated Review Open
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis characterized by asthma, eosinophilia, and necrotizing inflammation of small- to medium-sized vessels. Accumulating evidence indicates that EGPA is a polyge…
View article: Obinutuzumab in kidney transplantation: Past, present, and future
Obinutuzumab in kidney transplantation: Past, present, and future Open
Antibody-mediated rejection (ABMR) and recurrent primary renal disease (PRD) represent major causes of kidney transplant (KT) loss. The standard of care for desensitization, ABMR, and relapsing autoimmune glomerulopathies or nephrotic synd…
View article: Current immunotherapeutic approaches for relapsed/refractory follicular lymphoma: bispecific antibodies and CAR T-Cell therapies
Current immunotherapeutic approaches for relapsed/refractory follicular lymphoma: bispecific antibodies and CAR T-Cell therapies Open
Chemoimmunotherapy (CIT) combines anti-CD20 monoclonal antibodies with chemotherapy and has long been the standard first-line treatment for follicular lymphoma (FL). However, a significant subset of patients, particularly those who experie…
View article: Associations Between Th17 Cell Markers (IL-23R, CCR6, and IL-17) and Clinical Profiles in Sjögren’s Disease
Associations Between Th17 Cell Markers (IL-23R, CCR6, and IL-17) and Clinical Profiles in Sjögren’s Disease Open
Background/objectives: Sjögren’s disease (SjD) is an autoimmune disorder characterized by lymphocytic infiltration and inflammation leading to exocrine gland dysfunction. Th17 cells play a central role in autoimmune pathology and are defin…
View article: Long-term effectiveness and cost-effectiveness of testing for alemtuzumab antidrug antibodies to guide treatment in multiple sclerosis: a modelling study
Long-term effectiveness and cost-effectiveness of testing for alemtuzumab antidrug antibodies to guide treatment in multiple sclerosis: a modelling study Open
Biologic therapies are increasingly used in multiple sclerosis (MS), but often provoke anti-drug antibodies, potentially leading to treatment failure. Testing for anti-drug antibodies to guide treatment switching could improve clinical- an…
View article: Available datapackage for study 'A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia'
Available datapackage for study 'A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia' Open
This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
View article: Alemtuzumab en esclerosis múltiple remitente-recurrente en práctica clínica: seguimiento anual de NEDA-3 hasta 4 años
Alemtuzumab en esclerosis múltiple remitente-recurrente en práctica clínica: seguimiento anual de NEDA-3 hasta 4 años Open
View article: CTIM-24. SAFETY, EFFICACY, AND GENETIC PROFILING OF JL15003 IN RECURRENT GLIOBLASTOMA: A SINGLE-ARM OPEN-LABEL PHASE I CLINICAL TRIAL
CTIM-24. SAFETY, EFFICACY, AND GENETIC PROFILING OF JL15003 IN RECURRENT GLIOBLASTOMA: A SINGLE-ARM OPEN-LABEL PHASE I CLINICAL TRIAL Open
The oncolytic virus (OV) therapies against recurrent glioblastoma (rGBM) have been shown the promising clinical outcomes with good safety and extended overall survival. However, the genetic profile of OV therapy in rGBM is not clear yet. H…
View article: EXTH-88. A novel dual-antigen CAR T cell strategy targeting PDPN and GD2 for the treatment of glioblastoma
EXTH-88. A novel dual-antigen CAR T cell strategy targeting PDPN and GD2 for the treatment of glioblastoma Open
While chimeric antigen receptor (CAR) T cell therapy has achieved encouraging remission rates in hematologic malignancies, effective treatment of glioblastoma (GBM), the most common and most lethal primary malignant brain tumor in adults, …
View article: NCMP-35. ICANS and seizure-like activity observed after treatment with glofitamab in patient with diffuse large B-cell lymphoma: a case report
NCMP-35. ICANS and seizure-like activity observed after treatment with glofitamab in patient with diffuse large B-cell lymphoma: a case report Open
T-cell engagers represent a promising immunotherapy class that is increasingly being used to treat hematologic malignancies. Glofitamab is a bispecific monoclonal antibody that binds both CD20 receptors on B cells and CD3 receptors on T ce…
View article: Effect of Pre-Conditioning Clofarabine on Engraftment and Cell Recovery in Allogeneic Transplantation Using Post-Transplant Cyclophosphamide
Effect of Pre-Conditioning Clofarabine on Engraftment and Cell Recovery in Allogeneic Transplantation Using Post-Transplant Cyclophosphamide Open
Background Allogeneic hematopoietic cell transplant (allo-HCT) offers curative potential for high-risk leukemia. Infections, graft-versus-host disease (GVHD), and disease relapse after allo-HCT remain major obstacles to successful treatmen…
View article: Successful alemtuzumab retreatment in multiple sclerosis following previous diffuse alveolar haemorrhage
Successful alemtuzumab retreatment in multiple sclerosis following previous diffuse alveolar haemorrhage Open
Alemtuzumab-induced diffuse alveolar haemorrhage (DAH) is a rare but serious complication in people with relapsing-remitting multiple sclerosis (RRMS). Evidence supporting retreatment despite adverse events remains limited. We report a 29-…
View article: Granulocyte colony‐stimulating factor may improve engraftment in adults with sickle cell disease undergoing non‐myeloablative haematopoietic stem cell transplantation
Granulocyte colony‐stimulating factor may improve engraftment in adults with sickle cell disease undergoing non‐myeloablative haematopoietic stem cell transplantation Open
View article: Comparative effectiveness of disease-modifying therapies for highly active relapsing-remitting multiple sclerosis despite previous treatment – a systematic review and network meta-analysis
Comparative effectiveness of disease-modifying therapies for highly active relapsing-remitting multiple sclerosis despite previous treatment – a systematic review and network meta-analysis Open
View article: Belatacept Pharmacokinetic Analysis of Belatacept Early Steroid Withdrawal Trial (BEST) to Clinical Outcomes and Compared With Reported BENEFIT and BENEFIT‐EXT Pharmacokinetic Analysis
Belatacept Pharmacokinetic Analysis of Belatacept Early Steroid Withdrawal Trial (BEST) to Clinical Outcomes and Compared With Reported BENEFIT and BENEFIT‐EXT Pharmacokinetic Analysis Open
Belatacept (BELA) pharmacokinetic (PK) studies informed dosing strategies used in phase 3 studies, where fixed mg/kg dosing compared a less intensive (LI) and more intensive (MI) regimen. The LI regimen was preferred due to a better risk/b…
View article: Comparative efficacy and safety of induction therapy in solid organ transplantation: a systematic review and network meta-analysis
Comparative efficacy and safety of induction therapy in solid organ transplantation: a systematic review and network meta-analysis Open
Objective To comparatively evaluate the efficacy and safety of induction therapies in solid organ transplantation (SOT) using a Bayesian network meta-analysis (NMA). Methods Randomized controlled trials (RCTs) assessing induction therapies…
View article: Primary Progressive Multiple Sclerosis: New Therapeutic Approaches
Primary Progressive Multiple Sclerosis: New Therapeutic Approaches Open
Background and Purpose Primary progressive multiple sclerosis (PPMS) is a clinically different form of MS that causes gradual and irreversible neurological impairment from symptom onset without relapses or remissions. With a mean onset age…
View article: Real-world safety and effectiveness of alemtuzumab as a conditioning regimen for hematopoietic stem cell transplantation
Real-world safety and effectiveness of alemtuzumab as a conditioning regimen for hematopoietic stem cell transplantation Open
View article: Lymphoid Malignancies in Ataxia–Telangiectasia: Experience with Novel Targeted Therapies
Lymphoid Malignancies in Ataxia–Telangiectasia: Experience with Novel Targeted Therapies Open
Patients with ataxia–telangiectasia (AT) face unique challenges in managing lymphoid malignancies due to heightened sensitivity to chemotherapy and radiation, requiring alternative treatment strategies. This report presents three cases dem…
View article: Short-term outcome after simultaneous pancreas-kidney transplantation with alemtuzumab vs. basiliximab induction: a single-center retrospective study
Short-term outcome after simultaneous pancreas-kidney transplantation with alemtuzumab vs. basiliximab induction: a single-center retrospective study Open
View article: Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with <i>BCR::ABL1</i>-negative B-cell / myeloid mixed phenotype acute leukemia
Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with <i>BCR::ABL1</i>-negative B-cell / myeloid mixed phenotype acute leukemia Open
Not available.
View article: Clinical management of alemtuzumab-induced autoimmune thyroid diseases: a narrative review
Clinical management of alemtuzumab-induced autoimmune thyroid diseases: a narrative review Open
Alemtuzumab is a powerful anti-CD52 drug that is an established treatment option in patients with multiple sclerosis due to its proven efficacy. However, in about 50% of patients, the use of alemtuzumab is burdened by the development of se…
View article: Disease Course in Patients Switched from Natalizumab to Alemtuzumab: An Italian Multicenter, Prospective, Observational Study
Disease Course in Patients Switched from Natalizumab to Alemtuzumab: An Italian Multicenter, Prospective, Observational Study Open
Alemtuzumab is a valid exit strategy after natalizumab interruption.
View article: 12-Month Outcomes of a Prospective Randomized Trial Investigating Effects of IVIG on Top of rATG Versus rATG Alone in Pre-Sensitized Kidney Transplant Recipients: The INHIBIT Study
12-Month Outcomes of a Prospective Randomized Trial Investigating Effects of IVIG on Top of rATG Versus rATG Alone in Pre-Sensitized Kidney Transplant Recipients: The INHIBIT Study Open
Intravenous immunoglobulins (IVIG) are commonly used in peri-transplant desensitization, but evidence supporting their efficacy is limited. We conducted a prospective, randomized single-center, open-label, Phase IIIb non-inferiority clinic…
View article: Alemtuzumab Exposure and T Lymphocyte Depletion: A Population Pharmacokinetic‐Pharmacodynamic Model of Alemtuzumab Induction Therapy for Kidney Transplantation
Alemtuzumab Exposure and T Lymphocyte Depletion: A Population Pharmacokinetic‐Pharmacodynamic Model of Alemtuzumab Induction Therapy for Kidney Transplantation Open
Alemtuzumab is a T cell‐depleting monoclonal antibody that is used for the prevention of kidney transplant rejection. The duration of lymphodepletion after the current standard induction therapy dose is likely longer than necessary, result…
View article: Inefficiency Rates of Biological Immunosuppressive Induction Agents Used in Organ Transplantation: A Pharmacovigilance Study
Inefficiency Rates of Biological Immunosuppressive Induction Agents Used in Organ Transplantation: A Pharmacovigilance Study Open
Effective immunosuppressant pharmacotherapy is essential for successful organ transplantation. Background/Objectives: Generally, induction therapy includes basiliximab (BAS) or anti-thymocyte globulin (THY). However, other biological molec…